Thyroid Cancer

Latest News

Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.
FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

September 26th 2025

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.
How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

September 16th 2025

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.
Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

February 9th 2025

A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.
Thyroidectomy Shows Noninferiority Without Radioiodine in Thyroid Cancer

February 5th 2025

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer
Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

December 1st 2024

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

More News